Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.760
+0.050 (1.85%)
Apr 29, 2026, 4:08 PM HKT
14.52%
Market Cap 7.12B
Revenue (ttm) 763.16M
Net Income (ttm) -175.20M
Shares Out 1.04B
EPS (ttm) -0.17
PE Ratio n/a
Forward PE n/a
Dividend 0.03 (1.16%)
Ex-Dividend Date Jul 10, 2025
Volume 391,000
Average Volume 1,633,500
Open 2.770
Previous Close 2.710
Day's Range 2.710 - 2.770
52-Week Range 2.390 - 5.290
Beta 0.19
RSI 39.27
Earnings Date Apr 29, 2026

About HKG:1349

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technology drugs. The company was founded in 1996 and is based in Shanghai, the People's Republic of China. [Read more]

Sector Healthcare
Founded 1996
Employees 876
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1349
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.